Accelerating therapeutic antibody discovery to eradicate cancer
The ALADDIN project streamlines the process for an improved treatment of disease
An integrated platform for discovering therapeutic antibodies
We upgrade the current state-of-the-art techniques
Therapeutic antibodies (Abs) have shown to be efficient in the diagnosis and treatment of cancer. The ALADDIN research project combines various technologies related to the generation and identification of Abs into one single platform. This will significantly enhance the process, making it faster and more cost-effective than current solutions.
The ALADDIN consortium is formed by eight partners: research institutions, universities, and SMEs. The expertise of our team ranges from synthetic and molecular biology to mathematical modelling and microfluidics, ensuring a multidisciplinary approach for reaching our objectives.
This project has received funding from the EIC Pathfinder programme 2023 of the European Innovation Council (EIC) under Grant Agreement#101130574. This result only reflects the author’s view, and the EU is not responsible for any use that may be made of the information it contains.
